Section Arrow
Quote
ACIU.NASDAQ
- AC Immune SA
Quotes are at least 15-min delayed:2025/11/04 07:40 EST
Pre Market
Last
 3.18
0 (0.00%)
Bid
3.2
Ask
3.4
High 3.18 
Low 3.16 
Volume 202 
Regular Hours
Last
 3.18
-0.2 (-5.92%)
Day High 
3.35 
Prev. Close
3.38 
1-M High
4 
Volume 
236.46K 
Bid
3.2
Ask
3.4
Day Low
3.11 
Open
3.35 
1-M Low
2.63 
Market Cap 
340.03M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.22 
20-SMA 3.27 
50-SMA 2.81 
52-W High 4 
52-W Low 1.4299 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.50/-0.80
Enterprise Value
344.43M
Balance Sheet
Book Value Per Share
0.93
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
27.31M
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
Pre Market 1.69 -0.17 -9.14%
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
Pre Market 2.38 -0.05 -2.06%
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
Pre Market 1.91 -0.04 -2.05%
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
Pre Market 5.25 -0.19 -3.49%
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Pre Market 3.01 -0.19 -5.94%
Quotes are at least 15-min delayed：2025/11/04 07:40 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.